Australia · Delayed Price · Currency is AUD Syntara Company Description
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia.
The company’s lead product candidate is SNT‐5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention.
It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation.
The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023.
Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
| Country | Australia |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Gary Phillips |
Contact Details
Address: 20A Rodborough Road Frenchs Forest, 2086 Australia | |
| Phone | 61 2 9454 7200 |
| Website | syntaratx.com.au |
Stock Details
| Ticker Symbol | SNT |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000312480 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gary Jonathan Phillips BPharm, MBA | Chief Executive Officer, MD and Director |
| Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. | Head of Drug Discovery |
| Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin | Head of Medical and Regulatory Affairs - Alliance Management |
| Dr. Jana Baskar | Chief Medical Officer |
| Timothy Luscombe B.Com., C.A. | Chief Financial Officer |
| Cameron David Billingsley BA, LLB (Hons.) | Company Secretary and General Counsel |
| Dr. Dieter Hamprecht | Head of Chemistry |